PRELIMINARY RESULTS OF DARATUMUMAB, CYCLOPHOSPHAMIDE, THALIDOMIDE AND DEXAMETHASONE: A QUADRUPLET INTENSIED TREATMENT FOR NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM) TRANSPLANT ELIGIBLE (TE) PATIENTS E.Q. Crusoé; M.A. Salvino; S.Q. Silva; H.H.M. Santos; A.S. Santos; A.M. Almeida; L.O. Vieira; C.A. Fonseca; L.F. Lucas; J.S. Leal; M.M. Santos; J.A. Santos; E. Adorno; V.T.M. Hungria; M.G.B. Arruda;

IMMUNE PROFILING EVALUATION OF NEWLY DIAGNOSE MULTIPLE MYELOMA (NDMM) TRANSPLANT ELIGIBLE (TE) PATIENTS TREATED WITH DARATUMUMAB, CYCLOPHOSPHAMIDE, THALIDOMIDE AND DEXAMETHASONE (DARA-CTD): PRELIMINARY RESULTS A.S. Santos; H.H.M. Santos; M.A. Salvino; S.Q. Silva; L.F. Lucas; A.M. Almeida; M.M. Santos; M.G.B. Arruda; A.J.L. Torres; E.Q. Crusoe;

Erratum on ``Eltrombopag as first-line treatment in severe aplastic anemia: a cost-effectiveness analysis from the Brazilian public healthcare system perspective¿ M.A. Salvino; C. Bonfim; R.T. Calado; H. Kim; J.F. Bertinato; P. Scheinberg;